Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259961 | 1.00 | NPC1 (0.73) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11350421 | 0.89 | RAB9A (0.82) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10236929 | 0.89 | RAB9A (0.82) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15565832 | 0.87 | RAB9A (0.69) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL210094 | 0.86 | MAPT (0.77) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9128908 | 0.86 | RAB9A (0.55) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL874405 | 0.85 | MAOB (0.69) | RAB9AALDH1A1SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL3729907 | 0.84 | NPC1 (0.75) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12086470 | 0.84 | RAB9A (0.80) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31482044 | 0.84 | MRGPRX4 (0.56) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080049-A1 | COMPOUND FOR INHIBITING ATX, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING ATX ACTIVITY-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-04-17 | — | — | WO | disclosed |
| US-20250011285-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2025-01-09 | — | — | US | disclosed |
| EP-3152204-B1 | CARBAMATE DERIVATIVES WHICH ARE BOTH PHOSPHODIESTERASE 4 (PDE4) ENZYME INHIBITORS AND MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHIESI FARM SPA (IT) | 2018-03-28 | — | — | EP | disclosed |
| EP-2928880-B1 | PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARM SPA (IT) | 2018-02-14 | — | — | EP | disclosed |
| EP-2928880-B1 | PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS AND MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARM SPA (IT) | 2018-02-14 | — | — | EP | disclosed |
| CN-104837828-B | It is used as the phenylethyl pyridine derivate of PDE4 inhibitor | 奇斯药制品公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-2882740-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9453048-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| WO-2014025759-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| EP-0397746-A1 | CONDENSATION POLYMERS CONTAINING METHINE ULTRAVIOLET RADIATION-ABSORBING RESIDUES AND SHAPED ARTICLES PRODUCED THEREFROM | EASTMAN KODAK COMPANY (US) | 1990-11-22 | — | — | EP | disclosed |
| EP-0326287-A2 | Condensation polymers containing methine ultraviolet radiation-absorbing residues and shaped articles produced therefrom | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006663-A1 | CONDENSATION POLYMERS CONTAINING METHINE ULTRAVIOLET RADIATION-ABSORBING RESIDUES AND SHAPED ARTICLES PRODUCED THEREFROM | EASTMAN KODAK COMPANY (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4845187-A | POLYESTERS | EASTMAN KODAK COMPANY (US) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP19A1, CYP11B2 | NPC1 695/4885RAB9A 2559/4885ALDH1A1 188/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | NPC1 670/4885RAB9A 1723/4885ALDH1A1 2656/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | NPC1 620/4885RAB9A 2020/4885ALDH1A1 2495/4885 |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | NPC1 965/4885RAB9A 2255/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.